Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 HPIV3/ΔHNF/EbovZ GP Ebola Vaccine in Healthy Adults
NCT03462004Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2018
- Primary completion
- Mar 2019
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of human parainfluenza virus type 3 Ebola vaccine in Ebola virus disease (EVD) (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of vaccine-related solicited adverse events at Day 35, Area under the curve of nasal virus shedding after each dose of vaccine at Day 35 and 1 more. Started Mar 2018; status: terminated.
02
Drugs
human parainfluenza virus type 3 Ebola vaccine
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT03462004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462004.